CLLS

Cellectis S.A. ADR (CLLS) | Rumor.io

Cellectis

CLLS

Attention (50-day avg)0%

Attention rank (50-day avg)#1,927

Bullish sentiment (50-day avg)50%

Price to earnings ratio-2.21

Market capitalization149.1M

Earnings per share-0.64

Dividend yield (TTM)—

Revenue (annual)72.9M

Net income (annual)-67.6M

Social

What share of all stock conversation is about CLLS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Sep 14

Cellectis S.A. ($CLLS) has announced a strategic transformation to become an in vivo gene editing company, focusing on developing long-lasting treatments for chronic diseases.
The company has exited its CAR-T program and will instead focus on two preclinical in vivo candidates, HEAL-101 and HEAL-201, with initial Phase 1 readouts expected in H2 2027 and H1 2028, respectively.
Cellectis has partnered with $IOVA to develop its in vivo gene editing programs, and the company's market capitalization and enterprise value have been affected by the strategic transformation.

Generated by AI

Sentiment

Of the messages about CLLS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +92	8.16% -91.84	68.22% -13.43
Bearish	—	0% -92	91.84% +91.84	31.78% +13.43

Bullish· Mar 14

Cellectis S.A. (CLLS) has a strong financial position, with a cash runway into 2027 and expected licensing revenue from its partnership with AstraZeneca.
The company's partnership with AstraZeneca is expected to bring a gene therapy breakthrough, and the stock is showing early signs of bullish momentum with an uptick in price and volume.
CLLS has a healthy valuation with a price-to-book ratio that is in line with its bio stock peers, and is expected to reach $3-4 per share based on its multiple pipeline and strong fundamentals.

Bearish· Nov 2

$CLLS has been experiencing a strong selling pressure, with sellers sending block orders and causing a risk of a sharp price drop.
The asset's attempts to move higher are being met with selling, indicating a lack of strength in the market.
The presence of a large number of shorts and profit takers is contributing to the bearish sentiment, with some traders expecting a significant price drop.

Generated by AI

Topics

Of the messages about CLLS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	82.31%	73.77%
Technical Analysis	0%	0%	0%	14.26%
Analysts	0%	0%	17.69%	8.28%
Controversies	0%	0%	0%	3.53%
Earnings	0%	0%	0%	0.15%
Macro	0%	0%	0%	0%

Earnings· Aug 1

Cellectis S.A. ($CLLS) reported Q2 EPS of $0.03, missing expectations.
The company's Q2 revenue results were also below forecast.
$CLLS's earnings report highlighted a miss on revenues.

Announcements· Sep 14

Cellectis has announced a strategic transformation to become an in vivo gene editing company, focusing on developing long-lasting treatments for chronic diseases.
The company is exiting its CAR-T assets and pivoting to in vivo gene editing, with initial Phase 1 readouts expected in H2 2027 and H1 2028 for its HEAL-101 and HEAL-201 programs, respectively.
Cellectis has approved a strategic transformation to become an in vivo gene editing company, citing a shifting landscape in the industry and a decision to offload its lead CAR-T programs.

Technical Analysis· Nov 2

$CLLS is forming a wedge pattern on the 5-minute chart, with a possible bullish outcome if it holds above $2.80 on the hourly chart.
A double bottom pattern is forming on $CLLS, with a target price of $4.08, and the stock is showing strength by maintaining its lows on every down move.
$CLLS is forming a bullish pennant pattern, with a target price of $4.08, and has a strong support level at $3.28 on the 15-minute chart.

Generated by AI

Community

Of the messages about CLLS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	90.91%	68.24%	70.1%
Newcomers	0%	9.09%	31.76%	29.9%

Regulars· Sep 14

Cellectis has announced a strategic transformation to become an in vivo gene editing company, focusing on developing long-lasting treatments for chronic diseases.
The company will exit its CAR-T assets and shift its resources to in vivo gene-editing programs, with initial Phase 1 readouts expected in H2 2027 and H1 2028 for two preclinical candidates.
Cellectis' board has approved this transformation, citing a shifting landscape in the industry as the reason for choosing to pivot to in vivo gene editing.

Newcomers· Oct 16

The company is focusing on its CAR-T therapy, with strong early clinical results and a partnership with a pharma company, which has shifted the narrative from speculative to execution.
The stock has seen a significant increase in trading volume, with some users noting that the clinical breakthrough and partnership have investors re-stepping in, and others highlighting the potential for a squeeze due to reduced short interest.
The company's gene-editing pipeline and partnership network have been strengthened through a strategic collaboration with AstraZeneca, which may redefine next-gen CAR-T architecture and provide a significant catalyst for the stock.

Generated by AI

Cellectis S.A. (NASDAQ:CLLS) announced on September 14 that its board approved a strategic transformation on September 11. It will exit internal development of lasme-cel and eti-cel, seek partners for those cancer therapies, and prioritize two preclinical programs for severe lipid disorders. The shift moves the internal pipeline toward in vivo treatment, delivering editing machinery directly […]

13d agoYahoo Finance

Cellectis stock tumbles after Barclays double downgrade

13d agoInvesting.com

Cellectis Stock: An 'All Or Nothing' Pivot To In-Vivo Gene Editing Is Worth Monitoring

Cellectis pivots to in vivo gene editing, exiting ex-vivo CAR-T programs due to shrinking commercial opportunities. Read why CLLS stock is a hold.

13d agoSeeking Alpha

Barclays cuts Cellectis stock rating on gene editing concerns

14d agoInvesting.com

Cellectis stock downgraded at Citizens (CLLS:NASDAQ)

14d agoSeeking Alpha

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

14d agoBenzinga

Also Discussed

Investors talking about CLLS also mention

#	Name	Attention
1	BLCM - Bellicum Pharmaceuticals, Inc.	——
2	BLUE - bluebird bio, Inc.	——
3	Fate Therapeutics Inc.FATE	0%new
4	SGMO - Sangamo Therapeutics, Inc.	——
5	Editas Medicine, Inc.EDIT	0%+0
6	Novartis AG Sponsored ADRNVS	0%-0.01
7	Intellia Therapeutics, Inc.NTLA	0%+0
8	Precision BioSciences, Inc.DTIL	0%new
9	Agios Pharmaceuticals, Inc.AGIO	0%0
10	ICPT - Intercept Pharmaceuticals, Inc.	——

Cellectis S.A. ADR

Healthcare
Biotechnology

Cellectis S.A. ADR is a clinical-stage biotechnology company focused on gene editing and cell therapy. Cellectis develops gene-edited, off-the-shelf immunotherapies designed to target cancer, with a portfolio centered on allogeneic CAR T-cell product candidates and other engineered cell and gene therapy programs. Its current work spans hematologic cancers and select solid tumor indications, using proprietary genome-editing technology to create therapies that can be manufactured in a standardized form. The company also advances gene-edited hematopoietic stem and progenitor cell research for additional therapeutic applications. Based in Paris, France, Cellectis serves the biopharmaceutical sector by contributing specialized platforms and product candidates that support the broader development of next-generation cancer and gene therapy treatments.

Website

Location

8, rue de la Croix Jarry

Paris, 75013

France

Social

What share of all stock conversation is about CLLS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Sep 14

Cellectis S.A. ($CLLS) has announced a strategic transformation to become an in vivo gene editing company, focusing on developing long-lasting treatments for chronic diseases.
The company has exited its CAR-T program and will instead focus on two preclinical in vivo candidates, HEAL-101 and HEAL-201, with initial Phase 1 readouts expected in H2 2027 and H1 2028, respectively.
Cellectis has partnered with $IOVA to develop its in vivo gene editing programs, and the company's market capitalization and enterprise value have been affected by the strategic transformation.

Generated by AI

Sentiment

Of the messages about CLLS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +92	8.16% -91.84	68.22% -13.43
Bearish	—	0% -92	91.84% +91.84	31.78% +13.43

Bullish· Mar 14

Cellectis S.A. (CLLS) has a strong financial position, with a cash runway into 2027 and expected licensing revenue from its partnership with AstraZeneca.
The company's partnership with AstraZeneca is expected to bring a gene therapy breakthrough, and the stock is showing early signs of bullish momentum with an uptick in price and volume.
CLLS has a healthy valuation with a price-to-book ratio that is in line with its bio stock peers, and is expected to reach $3-4 per share based on its multiple pipeline and strong fundamentals.

Bearish· Nov 2

$CLLS has been experiencing a strong selling pressure, with sellers sending block orders and causing a risk of a sharp price drop.
The asset's attempts to move higher are being met with selling, indicating a lack of strength in the market.
The presence of a large number of shorts and profit takers is contributing to the bearish sentiment, with some traders expecting a significant price drop.

Generated by AI

Topics

Of the messages about CLLS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	82.31%	73.77%
Technical Analysis	0%	0%	0%	14.26%
Analysts	0%	0%	17.69%	8.28%
Controversies	0%	0%	0%	3.53%
Earnings	0%	0%	0%	0.15%
Macro	0%	0%	0%	0%

Earnings· Aug 1

Cellectis S.A. ($CLLS) reported Q2 EPS of $0.03, missing expectations.
The company's Q2 revenue results were also below forecast.
$CLLS's earnings report highlighted a miss on revenues.

Announcements· Sep 14

Cellectis has announced a strategic transformation to become an in vivo gene editing company, focusing on developing long-lasting treatments for chronic diseases.
The company is exiting its CAR-T assets and pivoting to in vivo gene editing, with initial Phase 1 readouts expected in H2 2027 and H1 2028 for its HEAL-101 and HEAL-201 programs, respectively.
Cellectis has approved a strategic transformation to become an in vivo gene editing company, citing a shifting landscape in the industry and a decision to offload its lead CAR-T programs.

Technical Analysis· Nov 2

$CLLS is forming a wedge pattern on the 5-minute chart, with a possible bullish outcome if it holds above $2.80 on the hourly chart.
A double bottom pattern is forming on $CLLS, with a target price of $4.08, and the stock is showing strength by maintaining its lows on every down move.
$CLLS is forming a bullish pennant pattern, with a target price of $4.08, and has a strong support level at $3.28 on the 15-minute chart.

Generated by AI

Community

Of the messages about CLLS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	90.91%	68.24%	70.1%
Newcomers	0%	9.09%	31.76%	29.9%

Regulars· Sep 14

Cellectis has announced a strategic transformation to become an in vivo gene editing company, focusing on developing long-lasting treatments for chronic diseases.
The company will exit its CAR-T assets and shift its resources to in vivo gene-editing programs, with initial Phase 1 readouts expected in H2 2027 and H1 2028 for two preclinical candidates.
Cellectis' board has approved this transformation, citing a shifting landscape in the industry as the reason for choosing to pivot to in vivo gene editing.

Newcomers· Oct 16

The company is focusing on its CAR-T therapy, with strong early clinical results and a partnership with a pharma company, which has shifted the narrative from speculative to execution.
The stock has seen a significant increase in trading volume, with some users noting that the clinical breakthrough and partnership have investors re-stepping in, and others highlighting the potential for a squeeze due to reduced short interest.
The company's gene-editing pipeline and partnership network have been strengthened through a strategic collaboration with AstraZeneca, which may redefine next-gen CAR-T architecture and provide a significant catalyst for the stock.

Generated by AI

Cellectis

Social

Sep 14

Bullish· Mar 14

Bearish· Nov 2

Earnings· Aug 1

Announcements· Sep 14

Technical Analysis· Nov 2

Regulars· Sep 14

Newcomers· Oct 16

Cellectis (CLLS) Exits Two CAR-T Programs. Can Gene Editing Justify the Clinical Reset?

Cellectis stock tumbles after Barclays double downgrade

Cellectis Stock: An 'All Or Nothing' Pivot To In-Vivo Gene Editing Is Worth Monitoring

Barclays cuts Cellectis stock rating on gene editing concerns

Cellectis stock downgraded at Citizens (CLLS:NASDAQ)

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Also Discussed

Cellectis S.A. ADR

Company Information

Location

Cellectis (CLLS) Exits Two CAR-T Programs. Can Gene Editing Justify the Clinical Reset?

Cellectis stock tumbles after Barclays double downgrade

Cellectis Stock: An 'All Or Nothing' Pivot To In-Vivo Gene Editing Is Worth Monitoring

Barclays cuts Cellectis stock rating on gene editing concerns

Cellectis stock downgraded at Citizens (CLLS:NASDAQ)

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Also Discussed

Social

Sep 14

Bullish· Mar 14

Bearish· Nov 2

Earnings· Aug 1

Announcements· Sep 14

Technical Analysis· Nov 2

Regulars· Sep 14

Newcomers· Oct 16